American Society for Biochemistry and Molecular Biology Selects … – Newswise (press release)

Newswise The American Society for Biochemistry and Molecular Biology announced this week the election and appointment of seven new society leaders. They begin their terms July 1.

President-elect

Gerald Hart, Johns Hopkins School of Medicine, who studies nutrient regulation of signaling and transcription.

Council

Takita Sumter, Winthrop University, who studies high-mobility group A proteins in cancer signaling.

JoAnn Trejo, University of California, San Diego, who studies G proteincoupled-receptor signal transduction.

Publications committee

Brian Crane, Cornell University, who studies molecular mechanisms of signal transduction.

Ruth Welti, Kansas State University, who studieslipid metabolism and plant response to environmental stress.

Nominating committee

Anthony Kossiakoff, University of Chicago, who studiesligand-induced receptor activation, antibody engineering and drug delivery.

Iqbal Hamza, University of Maryland, who studies heme trafficking in iron homeostasis.

Note to reporters and PIOs: Print-quality images are available upon request. Email Angela Hopp at ahopp@asbmb.org.

###

About the American Society for Biochemistry and Molecular Biology

The ASBMB is a nonprofit scientific and educational organization with more than 12,000 members worldwide. Most members teach and conduct research at colleges and universities. Others conduct research in various government laboratories, at nonprofit research institutions and in industry. The Societys student members attend undergraduate or graduate institutions. For more information about ASBMB, visit http://www.asbmb.org.

Original post:
American Society for Biochemistry and Molecular Biology Selects ... - Newswise (press release)

When will ‘Grey’s Anatomy’ season 14 premiere? – Blasting News

"Grey's Anatomy" season 13 may have only just finished two weeks ago, but fans are already looking for details about season 14.Just when will the show premiere on #ABC? Unfortunately, only CBS has released its fall 2017 schedule dates right now, but it shouldn't be too long before ABC follows suit. We can work out a rough date to pencil in your diary for now, and share all we know about "#Grey's Anatomy" season 14 so far.

Based on last season, a rough start date for season 14 will be September 28. We know that the show is definitely returning to its usual Thursday night 8 p.m. slot. Why change something that clearly isn't broken? It will also be the first of three Shonda Rhimes shows, with the final season of "Scandal" and then "How to Get Away with Murder" following on.

There is a lot of hype around one of Rhimes' newest planned shows. She plans to create a "Grey's" spinoff focused on firefighters, nicknamed "Seattle Fire." Very little is known about that so far.

One of the biggest storylines to focus on for "Grey's Anatomy" season 14 will be Megan Hunt's arrival. Previously believed dead, it turned out that Owen's sister and Riggs' ex-fiancee was actually held captive. She has been found and is now in Seattle for recovery.

This changes everything for our two doctors. Owen and Riggs are already suffering from the guilt of believing that she was dead. However, Owen still has issues with Amelia to discuss and those discussions can't happen now. Riggs had also started dating Meredith, but Meredith made it clear to put Megan first.

Throughout season 13, Maggie was in a love triangle without even knowing.

She liked Riggs, but Riggs and Meredith had already started hooking up. She'd only just gotten over the feeling of betrayal before finding out that Jackson is interested in her. This puts her in an awkward position again, as April clearly isn't happy with this development.

Fans aren't happy with the reveal that Jackson likes Maggie. For many fans, it came out of the blue and it means Jackson and April won't get back together, despite hooking up in Montana. It is possible this storyline will change direction based on the fan response.

"Grey's Anatomy" season 14 will likely return on September 28 or close to that date. It will definitely be back on Thursdays on ABC for the fall 2017 schedule. What do you think will happen in season 14?

Go here to read the rest:
When will 'Grey's Anatomy' season 14 premiere? - Blasting News

Anatomy of the collusion lie – Power Line (blog)

Our friends at that American Greatness site are pushing back on the alleged collusion scandal narrative. Andy McCarthys Real collusion was the first in a series. Brandon Weichert and Chris Buskirks The anatomy of a lie (i.e., the Trump-Russia collusion scandal) is the second. It aims to tell how the Russia story evolved from a campaign talking point into a witch hunt in search of a crime. Weichert and Buskirk have also produced a 30-minute video to accompany their anatomy; the video is embedded in their essay.

The Weichert/Buskirk anatomy compiles a substantial amount of information and turns it into a narrative with links to relevant source materials. The video gives a timeline documenting how the claim that Donald Trump colluded with Russia in order to steal the 2016 U.S. presidential election evolved. It argues the falsity of the claims of collusion. By contrast, evidence points both to the corruption of Hillary Clinton with her email server and the Clinton Global Initiative as well as the Obama administrations abuse of power to spy on citizens working for the Trump campaign.

Continued here:
Anatomy of the collusion lie - Power Line (blog)

The American Academy of Anti-Aging Medicine (A4M) and Metabolic Medical Institute (MMI) have been – PR Newswire UK (press release)

The Fellowship in Metabolic and Nutritional Medicine is an interactive educational experience that combines modular training with hands-on clinical practice and web broadcasts, while instilling practitioners with the necessary knowledge and skills to effectively practice regenerative and functional medicine. The Fellowship is comprised of the latest findings and research in the areas of endocrinology, cardiology, neurology, nutrition, and a variety of other health fields, and is available to all physicians and healthcare practitioners with active medical licenses.

As the world's largest non-profit society of physicians and scientists committed to research that helps optimize the human aging process, along with the advancement of techniques and technologies that detect, prevent, and treat aging-related diseases, The American Academy of Anti-Aging Medicine has collaborated with MMI to provide the RCGP with high quality information and guidance. The A4M is dedicated to the education of all healthcare professionals, and is proud to be in its 25th year of providing first-class continuing education conferences on anti-aging, regenerative, and functional medicine.

A4M & MMI work collectively to ensure that general practitioners are fully equipped with the knowledge and clinical skills in order to provide the best standards of care for patients.

Tolearn more,registerfor events,enrollin training programs, orexhibitat an A4M Conference, please contact the office of The American Academy of Anti-Aging Medicine at:

Toll-Free - US Only:(888) 997-0112International:(561) 997-0112Email: internationalevents@a4m.com

SOURCE American Academy of Anti-Aging Medicine

http://www.a4m.com

Excerpt from:
The American Academy of Anti-Aging Medicine (A4M) and Metabolic Medical Institute (MMI) have been - PR Newswire UK (press release)

Why Mainstream Media Need to Be Careful About Criticizing Conservatives – HuffPost

Written by Dr. Gleb Tsipursky, Intentional Insights Co-Founder and President.

________________________________________________________________

Many mainstream media outlets criticized conservatives with a broad brush over the Montana Congressional special election winner Republican Greg Gianforte assaulting a reporter, Ben Jacobs. Yet, according to behavioral science research conducted by myself and others, such criticism may end up hurting the safety of journalists, instead of advancing freedom of the press and pursuit of the truth.

First, the facts of the incident itself. According to the evidence available, Gianforte grabbed Jacobs by the neck, slammed him to the ground, and punched him. The episode was witnessed and corroborated by multiple independent witnesses, including Fox News and BuzzFeed reporters. The local sheriff - who earlier gave a financial contribution to Gianfortes campaign - charged Gianforte with misdemeanor assault.

How did conservatives respond? The assault took place on the evening of May 24, and Fox News - which had a reporter on scene - quickly wrote up a fair and balanced account. The Fox News account specifically stated that at no point did any of us who witnessed this assault see Jacobs show any form of physical aggression toward Gianforte, which Fox News certainly did not have to do. In fact, the Fox News story contradicted the official statement offered by Gianfortes campaign, which accused Jacobs of starting the fight by grabbing Gianfortes wrist, a statement now widely seen as a lie. A conservative venue, TheBlaze, ran a piece critical of Gianfortes statement, and The New York Post ran a similar piece.

Many conservative politicians also responded in a worthy manner. Within 24 hours of the assault, Speaker of the House Paul Ryan stated that There's never a call for physical altercations... I think he should apologize." This length of time is quite reasonable, as Ryan needed to find out the relevant facts. Steve Daines, a Montana Senator and major supporter for Gianforte, also called on Gianforte to apologize, adding "I do not condone violence in any way. Under such pressure, Gianforte rescinded his earlier deceptive official statement and instead apologized, saying I should not have treated that reporter that way, and Im sorry Ben Jacobs.

Certainly, some conservatives did not respond well. The conservative radio show host Rush Limbaugh practiced victim-blaming, implying that Gianfortes actions were not a big deal because the journalist was being insolent and disrespectful. The Daily Caller, a prominent conservative website, ran a story about some Montana voters supporting Gianfortes actions. A former Republican congressman defended Gianforte.

Such problematic responses that appeared to condone or ignore violence against reporters do not represent the majority of conservative responses. Nonetheless, The New York Times ran a story entitled A reporter was body slammed, but some conservatives want the news media to apologize. Chris Cuomo of CNN had harsh words for the Republican Party on the morning after the incident, asking You know what I hear? Silence. Where is the GOP? The Philadelphia Inquirer carried a piece entitled In Trump's America, that reporter body slam didn't come out of nowhere.

Other mainstream venues downplayed condemnation by conservatives of Gianfortes behavior and emphasized those standing by him. The Washington Post, in its editorial responding to the incident, quoted Ryans words supporting the right of people from Montanan to elect their representative, while failing to mention that he demanded an apology. In turn, The Atlantic quoted a joke made by Republican Representative Mark Sanford, while conveniently forgetting that Sanfords response also condemned the culture of hostility toward the media that contributed to Gianfortes behavior .

Unfortunately, the content on these mainstream media venues fails to provide an accurate depiction of reality, which harms journalist safety. Most of the content does acknowledge - in the depths of each piece - that many conservatives condemned Gianfortes behavior. Yet behavioral science research on news consumption shows that 59 percent of Americans are casual readers who only read the headlines. Thus, many casual independent or conservative readers would fail to perceive the widespread condemnation by conservative leaders of Gianfortes assault.

This outcome harms the safety of journalists. Research shows that our minds interpret new information in accordance with our past beliefsa thinking error known as the confirmation bias. The confirmation bias is one of several thinking errorsknown in behavioral science scholarship as cognitive biasesthat lead to motivated reasoning, where people pre-select a certain conclusion and reach that conclusion regardless of the facts. Fortunately, we can fight the confirmation bias in such situations by evaluating the opinions of prominent influencers who have political motivations to support one side, but fail to do so or even support the other side. Such strategies have effectively changed peoples perspectives even in our current polarized environment. Unfortunately, many mainstream venues failed their readership by not conveying the data needed for them to draw accurate conclusions and thus advance press freedom.

Another problem comes from one of the strongest findings in behavioral science, which shows that human beings respond very strongly to positive reinforcement. Through the style of their coverage painting all conservatives with a broad brush, these mainstream venues fail to provide positive reinforcement to conservatives who behaved in a prosocial manner. Research suggests that optimal performance comes from a combination of internal and external motivations. External incentives according to research, are especially crucial for promoting prosocial behavior such as protecting freedom of the press.

A further issue is the equating of Trumps behavior with Gianfortes actions. Conservative venues such as Breitbart immediately took the opportunity to condemn such comparisons, and call out what the article depicted as media hypocrisy for failing to do the same when liberals used violence. As others have accurately pointed out, while Trumps actions help create a climate of hostility to the media, it is much more difficult to connect Gianfortes actions to Trumps words. Drawing such connections undermines the already-low media credibility. A much better model for reporting on this connection came from a conservative venue, The American Conservative. It ran a piece that accurately describes how the hostility to mainstream media among Republicans predated Trump, while acknowledging that Trump ramped up this hostility, and criticizing Gianforte for lacking anger management skills. Such reporting, by providing an accurate depiction that attributes only a small part of the blame to Trumps actions, helps protect journalists.

Next time, these mainstream venues need to provide accurate reporting to avoid undercutting their credibility, to praise prosocial behavior to create incentives and positive reinforcement, and to have all readers take away accurate impressions from their headlines. You can make a difference by writing letters to the editor and making social media posts asking journalists to commit to accurate
reporting and to take the Pro-Truth Pledge for the sake of protecting the safety and freedom of the press. What you can do right now is take the pledge yourself to show your own commitment to the truth.

P.S. Want less lies in politics? Take the Pro-Truth Pledge, encourage your friends to do so, and call on your elected representatives to take it!

_______________________________________________________________

Connect with Dr. Gleb Tsipursky on Twitter, on Facebook, and on LinkedIn, and follow his RSS feed and newsletter.

Start your workday the right way with the news that matters most.

Link:
Why Mainstream Media Need to Be Careful About Criticizing Conservatives - HuffPost

UB program for underrepresented minority students in biomedical PhD programs wins coveted renewal – UB News Center

BUFFALO, N.Y. The University at Buffalos ongoing efforts to recruit underrepresented students in science, technology, engineering and mathematics (STEM) to its PhD programs has received a major boost from the National Institutes of Health, which renewed a $2.3 million, 5-year grant to help fully fund scholarships.

The grant will pay for the first two years of graduate school in the biomedical and behavioral sciences for four students a year. Over the past five years, the program is credited with bringing 20 underrepresented students to UB. And more importantly, it is part of a pipeline of catalysts that is helping the university attract underrepresented students to prepare the next generation of scientists and professors.

These students are highly recruited by other universities, said Margarita Dubocovich, PhD, SUNY Distinguished Professor in the Department of Pharmacology and Toxicology in the Jacobs School of Medicine and Biomedical Sciences and senior associate dean for diversity and inclusion.

The grant is part of the Initiative for Maximizing Student Development (IMSD), a student development program for research-intensive institutions funded by NIHs National Institute of General Medical Sciences. The prestigious grant was awarded to only 21 PhD training programs.

Numerous departments involved

Students admitted into UB's IMSD can enroll in any of the following UB programs or departments: biological sciences; biomedical engineering; chemistry; psychology; pharmacology and toxicology; pharmaceutical sciences; the PhD program in biomedical sciences; and the graduate division at Roswell Park Cancer Institute.

Dubocovich said the grant combined with UBs Institute for the Strategic Enhancement of Educational Diversity (iSEED) and its Collaborative Learning and Integrated Mentoring in the Biosciences (CLIMB) program has helped UB recruit 37 underrepresented students in STEM and related fields to its graduate programs over the past five years. And the deans of seven schools at UB have pledged to fund one underrepresented student a year.

These PhD graduate students are a cohort that helped win the grant renewal, she said. Helping diversify the ranks of the graduate programs has ramifications across the university.

When you recruit faculty, and they know we are actively recruiting underrepresented students, they are more apt to come here, Dubocovich said. They want to have a more diverse class.

National recruitment

Renewal of the grant was a significant win for the efforts of Dubocovich and her co-leader in the recruitment efforts, Rajendram V. Rajnarayanan, PhD, assistant professor of pharmacology and toxicology.

We must be doing something right, said Rajnarayanan, who likens the IMSD grant to a biological catalyst that helps keep students moving toward successful graduation and leadership roles in their scientific communities.

Dubocovich and Rajnarayanan attend conferences and speak to college groups to help recruit students to the university. In addition, they have established programs to bring promising undergraduate students to campus in the summer for a research training program.

We go and visit schools and speak passionately about research, so the students see it and want to be involved, said Rajnarayanan. Thats how it works.

We recruit nationally, Dubocovich said. We bring them here so they can learn about UB and see whether they want to come here for graduate school.

Owing to the IMSD program, the number of admissions offers made to students from diverse backgrounds has more than doubled, she said. The total number of underrepresented PhD students with thesis mentors in the Department of Pharmacology and Toxicology increased from 18 percent (2 out of 11) in 2011 to 58 percent (11 out of 19) in fall 2016.

Similarly, first year student enrollment in the PhD program in biomedical sciences has increased from 8 percent in 2008-2011 to 24 percent in 2012-2015. Together, these datahighlight the broader impact of the IMSD program in student enrollment at UB.

First two years are key

Rajnarayanan said the university has built a pipeline for the students, starting with the summer program and continuing through graduate school, that includes mentoring and research opportunities. Under the IMSD grant, PhD students have individual mentoring during the first two years of the program, and gather as a group regularly.

Statistically, if a student makes it through the first two years, they stay for the entire program, he said.

All students seeking an IMSD grant must first be accepted into a PhD program, and then the individual school that nominated them for the grant. Each year, up to 18 students are nominated and out of those, four students are accepted.

Continued here:
UB program for underrepresented minority students in biomedical PhD programs wins coveted renewal - UB News Center

People trust science. So why don't they believe it? – WGRZ-TV

Alia E. Dastagir , USA TODAY , TEGNA 12:48 PM. EDT June 02, 2017

Members of the Union for Concerned Scientists pose for photographs with Muppet character Beaker in front of The White House before heading to the National Mall for the March for Science rally in Washington, D.C. (Photo: Jessica Kourkounis, Getty Images)

Editor's note: This story was originally published in April. It has been updated to include the latest on the Paris climate agreement.

Thousands of scientists and their allies filled the streets of the nations capital onEarth Day for theMarch for Science, advocating for the importance of scientific truth in an era weve ominously been told doesnt value the truth any longer. Just a week later, the People's Climate March in Washington, D.C., demanded policymakers not only respect science, but that they also act on it.

And now, drawing global dismay and condemnation,President Trump has announced that the U.S. willno longer participate in the landmark Paris climate agreement.

Advocates say science is under attack. President Trumps Environmental Protection Agency chief Scott Pruitt doesnt accept evidence that shows humans are causing climate change.Education Secretary Betsy DeVos'2001 commentson wanting to advance Gods kingdom through education have educatorsworried she could undermine the teaching of evolution in public schools.Trumps budget blueprint slashes funding for the National Institutes of Health and the Department of Energy's Office of Science.

Esteemed astrophysicist Neil deGrasse Tyson, in an impassioned video on hisFacebook page, said he fears people have lost the ability to judge what's true and what's not.

"That is a recipe for the complete dismantling of our informed democracy," he says.

The scientific community is alarmed by the Trump administration, and by whatthey see as the diminishing role of objectivescience in American life. But theGeneral Social Survey, one of the oldest and most comprehensive recurring surveys of American attitudes, shows that although trust in public institutions has declined over the last half century, science is the one institution that has not suffered any erosion of public confidence. Americans who say they have a great deal of confidence in science has hovered around 40% since 1973.

Many scientists say there is no war on their profession at all.

According to the 2016 GSS data released this month, people trust scientists more than Congress (6%) and the executive branch (12%). They trust them more than the press (8%). They have more trust in scientists than in the people who run major companies (18%), more than in banks and financial institutions (14%), the Supreme Court (26%) or organized religion (20%).

So why all the headlines about the "war on science"?

Though science still holds an esteemed place in America, there isa gapbetween what scientists and some citizens think a rift that is not entirely new on issues such as climate change, nuclear power, genetically modified foods, human evolution and childhood vaccines.

Americans dont reject science as a whole. People love the weather forecast. They love their smartphones. When people reject science, its because theyre asked to believe something that conflicts with a deeply held view, whether political (myparty does not endorse that), religious (my god didnot say that) or personal (that's not how I was raised).

Manyconservatives reject the science of man-madeclimate change, just as manyliberals reject the science that shows nuclear energy can safely combat it. The views we express signal which politicalgroup we belong to. The gap between what science shows and what people believe, sociologists say, is about our identity.

The issue of climate change isnt about what you know, said Dan Kahan, a professor of psychology and law at Yale and a member of the universitysCultural CognitionProject. Its about who you are.

Polarization has exacerbated our differences, andwe know some of whats to blame:Therise of social media. A more partisan press. A dearth of universally-accepted experts. And greater access to information, which Christopher Graves, president and founder of the Ogilvy Center forBehavioralScience, said does not tug us toward the center, but rather makes us more polarized.

A human being cannot grasp something as a fact if it in any way undermines their identity, Graves said. And that is animmutable human foible. These things have always been there, but not at scale."

The GSS data show confidence in institutions overall has been in decline since the 1970s, though political scientists are quick to caution that this is animperfect benchmark.

Brendan Nyhan, a political scientist atDartmouth College, said trust in the mid-20th century was unnaturally high and polarization was unnaturally low,bolstered by unusual growth in middle class income and a reduction of inequality, which is when the "20th century version of the American dream and the trust in government to produce it was fully mythologized."

There was an usually high level of trust that came out of World War II, before the turn towards a more cynical view ofthe institutions of society especially politics and media after Vietnam and Watergate,"Nyhan said.

So how much more polarization can we expect?

Social scientists aren't sure, but they agreeTrump complicates things.

"He really is an us-versus-them figure," Kahan said. "People arent thinking about the arguments. Theyre thinkingaboutwhat side they're on."

Think about the way you search for information. If youre a new mom who believes vaccines cause autism (and a number of women in your mommy group do, too) are you searching for research that shows whether they actually do, or are you Googling vaccines cause autism to find stories to affirm your belief? (Studies show there isno link between vaccines and autism.)

The mother above is probably motivated by fear. Suchmotivated reasoning,says political scientistCharles Taberof Stony Brook University, shows that we are all fundamentally biased.

You have a basic psychological tendency to perpetuate your own beliefs, he said to really discount anything that runs against your own prior views.

It gets even more complicated.Once weve convinced ourselves of something, research suggests factsdont appeal to us.A studyco-led by Nyhanfound that trying to correct a persons misperception can have a backfire effect. When you encounter facts that dont support your idea, your belief in that idea actually grows stronger.

So what if we did a better job teaching people how science works? Doesn't help, Kahan said. Research shows peoplewith the most science intelligence are also the most partisan.

Its not knowledge but curiosity, Kahan says, that makes us more likely to accept scientific truths. Arecent studythat Kahan led found people with more scientific curiosity were more likely to be open-minded about information that challenged their existing political views.

And arguing helps, too. ScientistsHugo Mercier and Dan Sperber contend in their new book,The Enigma of Reason,that reason isn't somethingthat evolved sohumans could solve problems on their own. It developed so we could work together.

Instead of forcing someone to agree that climate change is caused by humans, Graves said, you can stop once you agree that, for example, flooding in Florida is a problem, and that you have to fix it (the bipart
isanSoutheast Florida Regional Climate Change Compactcan teach us about that).

Marcia McNutt, an American geophysicist and president of the National Academy of Sciences, said she isnt worried about a crisis of science, though she hopes more people would understand science is about the unbiased search for truth" and that benefits everyone.

Being a scientist only means that when I have an intuition about something, I test that intuition, and see if Im right, she said. A very, very smart mentor told me once, I don't trust anyone who hasn't at least changed their mind once in their career.

Science, it appears, may havemore lessons for usthan we think.

2017 USATODAY.COM

Read the original post:
People trust science. So why don't they believe it? - WGRZ-TV

IBM's Watson – Best Doctor In The World? – Anti Aging News

The Watson supercomputer, created by technology company IBM, uses the power of artificial intelligence (AI) in ways that benefit mankind. In 2011, the world was introduced to the potential of AI when Watson won the title of world champion on the popular game show Jeopardy! In 2011.

Since then, Watsons developers have focused on customizing the AI for medical use. Programmers have integrated thousands of patient records, scores of medical texts, and all the content in the PubMed and Medline databases into Watsons working memory. In all, the AI has consumed 2 million pages of text that represent over 600,000 pieces of medical evidence, 25,000 training cases, and 14,700 hours of clinical training.

The Benefits of Using AI in Medical Diagnoses

AI programs, like Watson, are gaining importance in information-heavy fields, like medicine. The supercomputer is able to store more information than a human brain and can access the information more quickly. In addition, a computer-generated diagnosis is based on evidence and established fact, while human doctors may be swayed by cognitive biases or confidence issues.

The Watson AI uses an interface that allows users to speak to it in a natural way. The machine is able to gather and analyze information from patients and compare it to stored information. Based on this inquiry, the AI can then make an accurate diagnosis.

More than just comparing bits of information, the Watson supercomputer is able to form hypotheses independently. In a process that is similar to the way humans learn, the machine can then test and evaluate its own hypotheses, disregarding what doesnt work and adjusting for error.

In 2011, McAfee wrote about the advantages of using AI for medical purposes. AI diagnoses are based on the complete published body of medical knowledge, making it the most up-to-date medical resource. Diagnostic programs are also accurate, consistent, cost very little to operate, and can be used anywhere in the world.

AI: The Future in Medical Care

When using AI for diagnostics, a physician describes symptoms and other contributing factors to the program. The computer then mines patient history and its own databases, and along with test results and other pieces of medically relevant data, creates a hypothesis. The hypothesis is tested against its information on treatments, hospital records, and published studies and research. Once satisfied that the hypothesis is valid, Watson can then give a customized treatment plan for the patient.

While Watson has incredible capacity, only a few companies are taking advantage of it. MD Anderson Cancer Center uses AI to develop treatment plans for leukemia patients. The medical company WellPoint uses Watson-based software to allow patients to evaluate their doctors treatment plans.

Currently, the Watson AI is not able to fully use all of the information it has access to. Developers are working with the program to help it develop the mental agility and versatility of thought that makes human doctors so effective.

More:
IBM's Watson - Best Doctor In The World? - Anti Aging News

The American Academy of Anti-Aging Medicine (A4M) and Metabolic Medical Institute (MMI) have been – PR Newswire UK (press release)

The Fellowship in Metabolic and Nutritional Medicine is an interactive educational experience that combines modular training with hands-on clinical practice and web broadcasts, while instilling practitioners with the necessary knowledge and skills to effectively practice regenerative and functional medicine. The Fellowship is comprised of the latest findings and research in the areas of endocrinology, cardiology, neurology, nutrition, and a variety of other health fields, and is available to all physicians and healthcare practitioners with active medical licenses.

As the world's largest non-profit society of physicians and scientists committed to research that helps optimize the human aging process, along with the advancement of techniques and technologies that detect, prevent, and treat aging-related diseases, The American Academy of Anti-Aging Medicine has collaborated with MMI to provide the RCGP with high quality information and guidance. The A4M is dedicated to the education of all healthcare professionals, and is proud to be in its 25th year of providing first-class continuing education conferences on anti-aging, regenerative, and functional medicine.

A4M & MMI work collectively to ensure that general practitioners are fully equipped with the knowledge and clinical skills in order to provide the best standards of care for patients.

Tolearn more,registerfor events,enrollin training programs, orexhibitat an A4M Conference, please contact the office of The American Academy of Anti-Aging Medicine at:

Toll-Free - US Only:(888) 997-0112International:(561) 997-0112Email: internationalevents@a4m.com

SOURCE American Academy of Anti-Aging Medicine

http://www.a4m.com

The rest is here:
The American Academy of Anti-Aging Medicine (A4M) and Metabolic Medical Institute (MMI) have been - PR Newswire UK (press release)

Hillsboro Native Earns Honors At Vanderbilt – thejournal-news.net

Hillsboro native Dr. Nancy J. Cox was honored this spring as the first recipient of the Richard M. Caprioli Research Award. Dr. Cox is currently the director of the Vanderbilt Genetics Institute in Nashville, TN.

The daughter of the late Gene and Helen Cox, she is a 1974 graduate of Hillsboro High School and was selected as the second Hillsboro Education Foundation Distinguished Alumni Award recipient in 2002.

Dr. Cox earned her bachelor of science degree in biology from the University of Notre Dame in 1978 and her doctorate in human genetics from Yale University in 1982.

She completed a postdoctoral fellowship in genetic epidemiology at Washington University and was a research associate in human genetics at the University of Pennsylvania.

In 1987, she was hired at the University of Chicago. She was appointed full professor in the departments of medicine and human genetics in 2004 and chief of the section of genetic medicine the following year.

In 2012, she was named a University of Chicago Pritzker Scholar. In 2015, Dr. Cox was hired at Vanderbilt University School of Medicine as the Mary Phillips Edmonds Gray Professor of Genetics, founding director of the Vanderbilt Genetics Institute and director of the Division of Genetic Medicine in the Department of Medicine. She is a fellow of the American Association for the Advancement of Science

Throughout her career as a quantitative geneticist, Dr. Cox has sought to identify and characterize the genetic component to common human diseases and clinical phenotypes like pharmacogenomics traits (how genes affect drug response).

Her work has advanced methods for analyzing genetic and genomic data from a wide range of complex traits and diseases, including breast cancer, diabetes, autism, schizophrenia, bipolar disorder, Tourette syndrome, obsessive-compulsive disorder, stuttering and speech and language impairment.

Through the national Genotype Tissue Expression (GTEx) project, Dr. Cox also contributed to the development of genome predictors of the expression of genes, and she also has investigated the genetics of cardiometabolic phenotypes such as lipids, diabetes and cardiovascular disease.

With colleagues at the University of Michigan, Dr. Cox is generating content for the Accelerating Medicine Partnership between the National Institutes of Health (NIH), U.S. Food and Drug Administration, biopharmaceutical companies and non-profit organizations. The goal of the partnership is to identify and validate promising biological targets, increase the number of new diagnostics and therapies for patients, and reduce the cost and time it takes to develop them.

Dr. Cox is co-principal investigator of an analytic center within the Centers for Common Disease Genomics, another NIH initiative that is using genome sequencing to explore the genomic contributions to common diseases such as heart disease, diabetes, stroke and autism. A major resource for the Cox lab is Vanderbilts massive biobank, BioVU, which contains DNA samples from more than 230,000 individuals that are linked to de-identified electronic health records.

Dr. Cox is the author or co-author of more than 300 peer-reviewed scientific articles. She is former editor-in-chief of the journal Genetic Epidemiology, and is the current president of the American Society of Human Genetics.

For developing new methods that have aided researchers worldwide in identifying and characterizing of the genetic and genomic underpinnings of diseases and complex traits, Dr. Cox is the first recipient of the inaugural Richard M. Caprioli Research Award.

Dr. Cox and her husband, Dr. Paul Epstein live in Nashville, TN, and have two grown daughters, Bonnie Epstein and Carrie Epstein.

The rest is here:
Hillsboro Native Earns Honors At Vanderbilt - thejournal-news.net

One gene closer to regenerative therapy for muscular disorders – Medical Xpress

June 1, 2017 This microscopic image of fibroblast cells shows the induction of cell fusion by a newly described gene and its protein, called myomerger. Multi-nucleus cells expressing genes needed to form skeletal muscle can be seen in flower-like clumps forming as cells fuse together. Reporting results in Nature Communications, the researchers seek ways to develop regenerative therapies for muscle disorders by getting stem cells to fuse and form functioning skeletal muscle tissues. Credit: Cincinnati Children's

A detour on the road to regenerative medicine for people with muscular disorders is figuring out how to coax muscle stem cells to fuse together and form functioning skeletal muscle tissues. A study published June 1 by Nature Communications reports scientists identify a new gene essential to this process, shedding new light on possible new therapeutic strategies.

Led by researchers at the Cincinnati Children's Hospital Medical Center Heart Institute, the study demonstrates the gene Gm7325 and its protein - which the scientists named "myomerger" - prompt muscle stem cells to fuse and develop skeletal muscles the body needs to move and survive. They also show that myomerger works with another gene, Tmem8c, and its associated protein "myomaker" to fuse cells that normally would not.

In laboratory tests on embryonic mice engineered to not express myomerger in skeletal muscle, the animals did not develop enough muscle fiber to live.

"These findings stimulate new avenues for cell therapy approaches for regenerative medicine," said Douglas Millay, PhD, study senior investigator and a scientist in the Division of Molecular Cardiovascular Biology at Cincinnati Children's. "This includes the potential for cells expressing myomaker and myomerger to be loaded with therapeutic material and then fused to diseased tissue. An example would be muscular dystrophy, which is a devastating genetic muscle disease. The fusion technology possibly could be harnessed to provide muscle cells with a normal copy of the missing gene."

Bio-Pioneering in Reverse

One of the molecular mysteries hindering development of regenerative therapy for muscles is uncovering the precise genetic and molecular processes that cause skeletal muscle stem cells (called myoblasts) to fuse and form the striated muscle fibers that allow movement. Millay and his colleagues are identifying, deconstructing and analyzing these processes to search for new therapeutic clues.

Genetic degenerative disorders of the muscle number in the dozens, but are rare in the overall population, according to the National Institutes of Health. The major categories of these devastating wasting diseases include: muscular dystrophy, congenital myopathy and metabolic myopathy. Muscular dystrophies are a group of more than 30 genetic diseases characterized by progressive weakness and degeneration of the skeletal muscles that control movement. The most common form is Duchenne MD.

Molecular Sleuthing

A previous study authored by Millay in 2014 identified myomaker and its gene through bioinformatic analysis. Myomaker is also required for myoblast stem cells to fuse. However, it was clear from that work that myomaker did not work alone and needed a partner to drive the fusion process. The current study indicates that myomerger is the missing link for fusion, and that both genes are absolutely required for fusion to occur, according to the researchers.

To find additional genes that regulate fusion, Millay's team screened for those activated by expression of a protein called MyoD, which is the primary initiator of the all the genes that make muscle. The team focused on the top 100 genes induced by MyoD (including GM7325/myomerger) and designed a screen to test the factors that could function within and across cell membranes. They also looked for genes not previously studied for having a role in fusing muscle stem cells. These analyses eventually pointed to a previously uncharacterized gene listed in the database - Gm7325.

Researchers then tested cell cultures and mouse models by using a gene editing process called CRISPR-Cas9 to demonstrate how the presence or absence of myomaker and myomerger - both individually and in unison - affect cell fusion and muscle formation. These tests indicate that myomerger-deficient muscle cells called myocytes differentiate and form the contractile unit of muscle (sarcomeres), but they do not join together to form fully functioning muscle tissue.

Looking Ahead

The researchers are building on their current findings, which they say establishes a system for reconstituting cell fusion in mammalian cells, a feat not yet achieved by biomedical science.

For example, beyond the cell fusion effects of myomaker and myomerger, it isn't known how myomaker or myomerger induce cell membrane fusion. Knowing these details would be crucial to developing potential therapeutic strategies in the future, according to Millay. This study identifies myomerger as a fundmentally required protein for muscle development using cell culture and laboratory mouse models.

The authors emphasize that extensive additional research will be required to determine if these results can be translated to a clinical setting.

Explore further: Researchers turn stem cells into somites, precursors to skeletal muscle, cartilage and bone

More information: Nature Communications (2017). DOI: 10.1038/NCOMMS15665

Adding just the right mixture of signaling moleculesproteins involved in developmentto human stem cells can coax them to resemble somites, which are groups of cells that give rise to skeletal muscles, bones, and cartilage ...

A team led by Jean-Franois Ct, researcher at the IRCM, identified a ''conductor'' in the development of muscle tissue. The discovery, published online yesterday by the scientific journal Proceedings of the National ...

Athletes, the elderly and those with degenerative muscle disease would all benefit from accelerated muscle repair. When skeletal muscles, those connected to the bone, are injured, muscle stem cells wake up from a dormant ...

Johns Hopkins researchers report they have inadvertently found a way to make human muscle cells bearing genetic mutations from people with Duchenne muscular dystrophy (DMD).

Duchenne muscular dystrophy is a chronic disease causing severe muscle degeneration that is ultimately fatal. As the disease progresses, muscle precursor cells lose the ability to create new musclar tissue, leading to faster ...

Researchers at Sanford Burnham Prebys Medical Research Institute (SBP) have conclusively identified the protein complex that controls the genes needed to repair skeletal muscle. The discovery clears up deep-rooted conflicting ...

A University of California, Berkeley, study of mice reveals, for the first time, how puberty hormones might impede some aspects of flexible youthful learning.

The bacteria in a child's gut appears to be influenced as early as its first year by ethnicity and breastfeeding, according to a new study from McMaster University.

The human body runs according to a roughly 24-hour cycle, controlled by a "master" clock in the brain and peripheral clocks in other parts of the body that are synchronized according to external cues, including light. Now, ...

A detour on the road to regenerative medicine for people with muscular disorders is figuring out how to coax muscle stem cells to fuse together and form functioning skeletal muscle tissues. A study published June 1 by Nature ...

Cholesterol, a naturally occurring compound at the lung surface, has been shown to have a clear effect on the properties of this nanoscale film that covers the inside of our lungs. Cholesterol levels in this system may affect ...

Researchers from Monash University have developed a new drug delivery strategy able to block pain within the nerve cells, in what could be a major development of an immediate and long lasting treatment for pain.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more from the original source:
One gene closer to regenerative therapy for muscular disorders - Medical Xpress

Promise of precision medicine depends on overcoming big obstacles – Healthcare IT News

Paul Cerrato says he first started researching precision medicine almost 30 years ago.

"Back then it wasn't called precision medicine, but when I was in graduate school I did my final master's thesis on 'biochemical individuality' that was the buzzword," said Cerrato, a healthcare journalist. "That was the beginnings of the thinking about personalizing care: trying to understand how each human body is different before they can figure out how to treat individuals."

Fast forward three decades and the excitement around precision medicine seems to finallybe at a tipping point thanks to maturing technology, more cost-effective gene sequencing and momentum-building federal projects such as the Precision Medicine Initiative and the Cancer Moonshot.

[Also:How Penn Medicine primed its IT infrastructure for precision medicine]

But the obstacles are also substantial from the high cost of drugs for precision oncology, lack of widespread interoperability, skepticism on the part of some clinicians and challenges related to patient engagement.

At the Healthcare IT News Precision Medicine Summit in Boston on June 12, Cerrato, along with Beth Israel Deaconess Medical Center CIO John Halamka, MD, will discuss the obstacles and opportunities facing personalized medicine.

Halamka knows well about the opportunities. And not just because he's a renowned expert on health information technology. His wife, Kathy, was successfully treated for breast cancer with help from some sophisticated precision medicine tools and techniques.

Cerrato and Halamka just finished a book together, Realizing the Promise of Precision Medicine, due to be published by Elsevier in October. In it, they offer some insights into Kathy's treatment, but focus more generally on the transformative potential of personalized care, exploring the role of electronic health records, patient-facing mobile apps, health information exchange and more.

They're hopeful about the future. But cognizant that some substantial hurdles will need to be overcome along the way.

"When we were researching the book there was a lot of positive data, but also quite a bit of skepticism, and criticism of the whole concept that precision medicine should have such an important role in patient care," said Cerrato.

One of the central goals of their book, and their talk in Boston this month, is to counter the misapprehension of many clinicians that precision medicine has limited applications in the real-world care settings.

For instance, he said, many physicians argue: "'Personalized medicine? We already do that. We don't need to spend another $200 or $300 million on a precision medicine initiative because we already provide personalized care on a daily basis.'

"Of course, the answer to that is, that's personalized care with a lower-case P," said Cerrato. "We're talking about something much more sophisticated and much more involved: genomics and microbiome and lots of other risk factors. The average doc might be personalizing medicine by switching from one antibiotic to another, or asking patients if they have liver disease before they decide to use a statin, or those kinds of things. That's personalization, but those are the baby steps."

Another objection has less to do with changing culture and mindset and more to do with financial realities, he said. And this one in the near term, at least has some merit.

"The second obstacle we're dealing with is the objection of some thought leaders in clinical medicine that precision medicine will simply cost too much," said Cerrato. "There's some substance to that objection. You look at the cost of precision medicine drugs that have been coming out the past couple years they're really astronomical. And the return on investment, very often, is limited, especially in cancer care," where hugely expensive drugs are sometimes only able to prolong life for a few months or a year.

"It's a work in progress," he said. "We don't have a simple answer to that. But we've got to put it out there. One of the reasons we want to give a presentation like this and write a book like this is we want to convince docs in the trenches, and thought leaders in clinical care, that precision medicine really is a model they should be following. In order to do that, we really should be up front about their criticisms. We have to address them directly."

Another common concern is that "physicians' workloads would be greatly increased if they had to start practicing precision medicine on a daily basis," said Cerrato. "You're talking about mountains and mountains of information. How do you translate that so a physician who only has 15 minutes with a patient can use that in daily care?"

Again, not an unreasonable point to make. Gene sequencing is still pretty expensive, too. But even if it cost a dollar, the average primary care physician does not know how to interpret genomic data."

Technology also poses big challenges, especially while interoperability remains elusive. "Without interoperability, precision medicine is really not going to get too far."

EHRs too are lagging badly in their ability to handle data-intensive genomics. "Right now we're not at the stage where a physician can just open up his electronic health record and say 'OK, what does this patient's gene sequencing look like?' We're not there yet."

But there are big reasons for optimism, too. As Halamka said, Kathy's treatment benefited greatly from technologies such as Clinical Query 2, software at Beth Israel Deaconess that allows physicians to see anonymized health records of cohorts of patients, tailored by different demographic and clinical parameters.

"It looks at all the patients who have had similar signs and symptoms and lab values and shows what were the treatment recommendations for those patients," said Cerrato. "It allowed the oncology team to individualize the care for Kathy so it would meet her needs, while eliminating the possibility of her getting treated with a protocol that would do more harm than good."

Most precision medicine and genomics work is still being done at advanced academic medical centers such as BIDMC, of course.

But on a smaller scale, there's still big promise for other types of personalized treatments.

"There are certain aspects of the field that are already happening right now. Especially in the field of diabetes, there's enough out there in terms of mobile apps and other digital tools, that is allowing physicians who are interested to practice precision medicine today," said Cerrato.

"Scripps has come out with an app for asthmatics, and it does a lot of the heavy lifting for clinicians by allowing patents to put in some basic parameters about their peak flow readings and their medication use and a few other things," he added. "When a doc uses that for the asthmatic patient, they don't have to do all the work. The technology of the app will do it for them. It has built-in decision trees to help them make better decisions on a personalized basis."

The bottom line, said Cerrato, is that there are some aspects of precision medicine that are working for some docs now and there are some aspects that remain in the future either because they're not educated enough to know how to do it, or the clinical data is not there yet."

How long it takes for genomics and personalized treatments to become commonplace still depends on the answers to a host of clinical, financial, technological and cultural questions, he said, but "I do think it will be the standard of care in the future."

Twitter:@MikeMiliardHITN Email the writer: mike.miliard@himssmedia.com

Like Healthcare IT News on Facebook and LinkedIn

Go here to see the original:
Promise of precision medicine depends on overcoming big obstacles - Healthcare IT News

Here’s Why Editas Medicine Fell as Much as 15.7% Today – Motley Fool

What happened

Shares of gene editing pioneer Editas Medicine (NASDAQ:EDIT) dropped nearly 16% today after a new study published in Nature Methods drew attention to unintended effects of using the highly touted genetic engineering tool known as CRISPR. Shares of genome-editing peers CRISPR Therapeutics (NASDAQ:CRSP) and Intellia Therapeutics (NASDAQ:NTLA) were down as much as 6.9% and 14.9%, respectively, on the news.

The study, conducted by a team from Columbia University Medical Center, provided data showing that the technology can "introduce hundreds of unintended mutations into the genome," according to Genetic Engineering & Biotechnology News. That contradicts one of the better-known characteristics of CRISPR: precision.

Simply put, it's not sitting well with investors, who are (in knee-jerk fashion) adjusting the value placed on early-stage platforms, especially Editas Medicine, which will be the first of the group to enter clinical trials. As of 3:31 p.m. EDT, the stock had settled to a 11.3% loss.

Image source: Getty Images.

The study is among the first to quantify the specificity of CRISPR tools, which work by delivering gene editing enzymes to specific parts of the genome through the use of synthetic guide RNAs. Or that's how they're supposed to work. The authors of the study show that although intended edits can be made with respectable efficiency, such as correcting a mutation in a gene that causes blindness in mice, there are also unintended secondary edits made to the genome.

This may seem like a bombshell report, but it's a matter of optics. Researchers have never shied away from the reality that CRISPR gene editing tools can stray off target and make unintended edits to genomes in mammalian cells (i.e., humans). Many labs -- including Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics -- are working on increasing the efficiency and specificity of the technology. This is how science works. By quantifying these off-target mutations, which the paper attempted to do, researchers can begin to better understand how to improve the technology.

Investors and traders did not take the same cool-headed approach to the news, instead giving into a knee-jerk reaction to adjust the value of each pre-clinical technology platform. While off-target edits could prove troublesome for a CRISPR therapeutic used in humans, it's important to remember that there are currently no clinical trials underway in the United States. Editas Medicine will become the first to initiate a clinical trial later this year.

The sharp contrasts in reactions from researchers and investors is likely driven by how CRISPR is perceived by the media. Unfortunately, there is a generous amount of hyped-up science journalism that sticks to simple narratives -- "CRISPR has arrived and will cure all diseases!" -- instead of more nuanced takes that give equal weight to each current obstacles and future potential facing an emerging technology. Just remember: Biology is never quite so simple.

The results from the study don't really change anything, except for bringing more attention to the already existent clinical risk inherent to the development of early-stage CRISPR therapeutics. There is still plenty of work and new technology left to be developed before gene editing fulfills its promise in treating and curing human diseases. Hopefully, this can be a long-term positive for investors in CRISPR stocks by forcing them to listen to the fundamental hurdles for the technology. Hopefully.

Maxx Chatsko has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Go here to see the original:
Here's Why Editas Medicine Fell as Much as 15.7% Today - Motley Fool

A fresh math perspective opens new possibilities for computational chemistry – Phys.Org

June 1, 2017 by Linda Vu This image shows the structure of berkelium in oxidation state +IV. Researchers used the new Berkeley Lab algorithm to calculate the absorption spectrum and confirm what what several experimental results have been hintingthat the element berkelium breaks form with its heavy element peers by taking on an extra positive charge when bound to a synthetic organic molecule. This property could help scientists develop better methods for handling and purifying nuclear materials. Credit: Bert de Jong, Berkeley Lab

Glow-in-the-dark objects seem magical when you're a kidthey can brighten up a dark room without the need for electricity, batteries or a light bulb. Then at some point you learn the science behind this phenomenon. Chemical compounds called chromophores become energized, or excited, when they absorb visible light. As they return to their normal state, the stored energy is released as light, which we perceive as a glow. In materials science, researchers rely on a similar phenomenon to study the structures of materials that will eventually be used in chemical catalysis, batteries, solar applications and more.

When a molecule absorbs a photonthe fundamental particle of lightelectrons in the molecular system are promoted from a low-energy (ground) state to a higher-energy (excited) state. These responses resonate at specific light frequencies, leaving "spectral fingerprints" that illuminate the atomic and electronic structures of the system being studied.

In experiments, the "spectral fingerprints" or absorption spectrum, are measured with state-of-the-art facilities like the Advanced Light Source (ALS) at the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab). In computer simulations, these measurements are typically captured with a quantum mechanical method called Time Dependent Density Functional Theory (TDDFT). The computational models are critical in helping researchers make the most of their experiments by predicting and validating results.

Yet despite its usefulness, there are times when TDDFT cannot not be used to calculate the absorption spectrum of a system because it would require too much time and computer resources. This is where a new mathematical "shortcut" developed by researchers in Berkeley Lab's Computational Research Division (CRD) comes in handy. Their algorithm speeds up absorption calculations by a factor of five, so simulations that used to take 10 to 15 hours to compute can now be done in approximately 2.5 hours.

A paper describing this method was published in the Journal of Chemical Theory and Computation (JCTC). And the new approach for computing the absorption spectrum will be incorporated in an upcoming release of the widely used NWChem computational chemistry software suite later this year.

New Algorithms Lead to Computational Savings

To study the chemical structure of new molecules and materials, scientists typically probe the system with an external stimulustypically a laserthen look for small electronic changes. Mathematically, this electronic change can be expressed as an eigenvalue problem. By solving this eigenvalue problem, researchers can get a good approximation of the absorption spectrum, which in turn reveals the resonant frequencies of the system being studied. Meanwhile, the corresponding eigenvector is used to calculate how intensely the system responded to the stimulus. This is essentially the principle behind the TDDFT approach, which has been implemented in several quantum chemistry software packages, including the open-source NWChem software suite.

While this approach has proven to be successful, it does have limitations for large systems. The wider the energy range of electronic responses a researcher tries to capture in a system, the more eigenvalues and eigenvectors need to be computed, which also means more computing resources are necessary. Ultimately, the absorption spectrum of a molecular system with more than 100 atoms becomes prohibitively expensive to compute with this method.

To overcome these limitations, mathematicians in CRD developed a technique to compute the absorption spectrum directly without explicitly computing the eigenvalues of the matrix.

"Traditionally, researchers have had to compute the eigenvalues and eigenvectors of very large matrices in order to generate the absorption spectrum, but we realized that you don't have to compute every single eigenvalue to get an accurate view of the absorption spectrum," says Chao Yang, a CRD mathematician who led the development of the new approach.

By reformulating the problem as a matrix function approximation, making use of a special transformation and taking advantage of the underlying symmetry with respect to a non-Euclidean metric, Yang and his colleagues were able to apply the Lanczos algorithm and a Kernal Polynomial Method (KPM) to approximate the absorption spectrum of several molecules. Both of these algorithms require relatively low-memory compared to non-symmetrical alternatives, which is the key to the computational savings.

Because this method requires less computing power to achieve a result, researchers can also easily calculate the absorption spectrum for molecular systems with several hundreds of atoms.

"This method is a significant step forward because it allows us to model the absorption spectrum of molecular systems of hundreds of atoms at lower computational cost." says Niranjan Govind, a computational chemist at the Pacific Northwest National Laboratory who collaborated with the Berkeley Lab team on the development of the method in the NWChem computational chemistry program.

Recently Berkeley Lab scientists used this method to calculate the absorption spectrum and confirm what several experimental results have been hintingthat the element berkelium breaks form with its heavy element peers by taking on an extra positive charge when bound to a synthetic organic molecule. This property could help scientists develop better methods for handling and purifying nuclear materials. A paper highlighting this result appeared April 10 in the journal Nature Chemistry.

"The experimental results were hinting at this unusual behavior in berkelium, but there wasn't enough experimental evidence to say yes, 100 percent, this is what we're seeing," says study co-author Wibe Albert de Jong, a CRD scientist. "To be 100 percent sure, we did large computational simulations and compared them to the experimental data and determined that they were, indeed, seeing berkelium in an unusual oxidation state."

This new algorithm was developed through a DOE Office of Science-supported Scientific Discovery through Advanced Computing (SciDAC) project focused on advancing software and algorithms for photochemical reactions. SciDAC projects typically bring together an interdisciplinary team of researchers to develop new and novel computational methods for tackling some of the most challenging scientific problems.

"The interdisciplinary nature of SciDAC is a very effective way to facilitate breakthrough science, as each team member brings a different perspective to problem solving," says Yang. "In this dynamical environment, mathematicians, like me, team up with domain scientists to identify computational bottlenecks, then we use cutting-edge mathematical techniques to address and overcome those challenges."

Explore further: Supercomputing mimics berkelium experiments to validate new find

More information: Jiri Brabec et al. Efficient Algorithms for Estimating the Absorption Spectrum within Linear Response TDDFT, Journal of Chemical Theory and Computation (2015). DOI: 10.1021/acs.jctc.5b00887

The Titan supercomputer at the Oak Ridge Leadership Computing Facility (OLCF) has enabled scientists to explore an unexpected oxidation state in the rare, radioactive element berkelium that was first observed in experiment. ...

Supercomputers can calculate how a molecule's atoms move, giving insights for ast
rophysics, fuel use, and more. To determine a molecule's rotational and vibrational energies, chemists collect data about the positions of its ...

Most methods for the structural characterization of biomolecules, such as X-ray crystallography or electron microscopy, require static or crystallized samples. Attaching fluorescent molecules to protein surfaces, however, ...

Scientists at the Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) and the California Institute of Technology (Caltech) havein just two yearsnearly doubled the number of materials known to ...

For the first time, researchers at the Lawrence Berkeley National Laboratory (Berkeley Lab) have built and trained machine learning algorithms to predict defect behavior in certain intermetallic compounds with high accuracy. ...

New theoretical physics models could help us better grasp the atmospheric chemistry of ozone depletion. Indeed, understanding photoabsorption of nitrous oxide (N2O) - a process which involves the transfer of the energy of ...

Yale University scientists have developed a novel chemical process that may lead to the creation of a new class of antibiotics.

For a motor to power machinery, the local motion has to be translated into the ordered movement of other parts of the system. University of Groningen organic chemists led by professor Ben Feringa are the first to achieve ...

John Innes Centre scientists are among an international team who have discovered a new class of compounds that target bacteria in a unique way.

UK scientists have created a new method to structure peptides, which they say will be cheaper and make the process of using stapled peptides in drug discovery much more widely available.

EPFL scientists have built a low-cost and ultra-stable perovskite solar cell that has been running at 11.2 percent efficiency for over a year, without loss in performance.

The "clean energy economy" always seems to be a few steps away but never quite here. Most energy for transportation, heating and cooling and manufacturing is still delivered using fossil fuel inputs. But with a few scientific ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the rest here:
A fresh math perspective opens new possibilities for computational chemistry - Phys.Org

Genetic engineering through click chemistry – The Biological SCENE

Gene therapy and a range of biological research rely on the efficient delivery of nucleic acids into cells through the process known as transfection. Most widely-used transfection approaches for mammalian cells rely on electrostatic forces, usually taking advantage of cationic reagents to bind to negatively-charged nucleic acids and form strong ionic complexes. Cells then grab these complexes and internalize them through a process called endocytosis. However, the concentration of positive charge in the reagents can kill cells, and some cellssuch as embryonic cells, neurons, or cells directly isolated from tissuedont incorporate the nucleic acids successfully.

Now researchers report a novel transfection technique, SnapFect, that relies on bio-orthogonal moleculesa class of chemically-reactive molecules that dont interfere with biological systems (ACS Cent. Sci. 2017, DOI: 10.1021/acscentsci.7b00132). The team designed nanoparticle liposomes carrying a bio-orthogonal ligand. When they add those fatty particles to cell culture, they fuse into the cell membrane within seconds, leaving the ketone ligand exposed on the surface. The team then packages the nucleic acids to be delivered in complementary lipid complexes decorated with oxyamines. When the oxyamine particles are added to the cells, these functional groups react quickly with the cell surface ketones. The membrane-bound nucleic-acid complex is then pulled into the cell via endocytosis, and the nucleic acid can be expressed. Its not based on electrostatics but on click chemistry, says Muhammad N. Yousaf, a chemical biologist at York University. Thats why basically every cell is transfected with the nucleic acid.

Commercial transfection reagents already bring in about $1.5 billion per year. Yousafs team compared SnapFect to two widely-used kits: Lipofectamine (Life Technologies) and ViaFect (Promega). SnapFect transfected cells with a 68% overall efficiency while the other two transfected 19% and 29%, respectively.

Yousaf launched a company called OrganoLinX that this month began selling SnapFect ($350 for 20-25 transfections). We focused on making [the kit] just as easy to use as other commercial products out there, he says.

Besides improving efficiency, researchers could also pre-treat one batch of cells to decorate them with ketones and then mix them with other cell types before adding nucleic acids. Just the pre-treated ones will be transfected, Yousaf explains. Its like precision transfection. Because the team can create a variety of complexes using the oxyamine particles, the technique can also deliver other molecules such as proteins into cells.

I think its an interesting step forward, says James H. Eberwine, a molecular neurobiologist at the University of Pennsylvaniaparticularly the techniques universal applicability to DNA, RNA, and proteins, as well as the specificity conferred by the click chemistry approach.

Eberwine adds that while the study compares SnapFect to two widely-used techniques, researchers often optimize those techniques for their particular applications and achieve much higher efficiencies than those noted in this study. I would certainly try it, he says, and if it really does have the higher efficiency then I could see value in doing this.

Currently cell surface modification with ketones must occur shortly before addition of the oxyamine-bundled cargo. But SnapFect would be especially powerful if the ketone modification was more permanent, Eberwine says. That way, researchers could pre-engineer the surface of immature cells, then allow those cells to develop, migrate, and find their place in the local microenvironment of an experimental system before they get transfected. This would be a real boon, he says.

Read this article:
Genetic engineering through click chemistry - The Biological SCENE

Chemistry of the stars – Royal Society of Chemistry

Michael Leggett has been a member of his local astronomical society for several years. He tells us how he has been drawing on his chemistry background to deliver lectures on astrochemistry to astronomers.

My local astronomical society ran a survey to find out what subjects members might want covered. One member requested something about chemistry and I decided to prepare an introduction to astrochemistry as a series of short talks looking at one element at a time, its basic chemistry and aspects of interest to astronomers.

The series began in 2016 with the first short talk on hydrogen, and this was followed by a second short talk on the heavy hydrogen isotopes deuterium and tritium. The final short talk in 2016 was about helium and the noble gases.

The series will continue well into 2017 (possibly beyond) with the next short talk provisionally about lithium and the alkali metals. This will be followed by talks on beryllium, boron, carbon, nitrogen, oxygen, fluorine and their corresponding groups, with subsequent talks on selected transition metals, lanthanides and actinides.

I also regularly present talks for astronomical societies on chemical, biological and historical aspects of astronomy and astronautics.

The Orion Nebula, taken by a member of the Milton Keynes Astronomical Society, John Bell Picture: John Bell

More here:
Chemistry of the stars - Royal Society of Chemistry

MetroHealth Names Chemistry Agency of Record – PR Newswire – PR Newswire (press release)

MetroHealth has an acute care hospital with a Level I trauma and burn center and more than 25 locations throughout Cuyahoga County. MetroHealth is currently in the planning phase of building a new state-of-the-art hospital on the near west side of Cleveland, a massive $1billion project that is expected to open in 2022. The new facility will be the centerpiece of the system's 52-acre campus that will undergo a complete transformation over the next five years.

"We are developing an integrated strategy to help MetroHealth evolve its brand and increase primary care services throughout Cuyahoga County," said Ned Show, CEO of Chemistry. "MetroHealth is focused on keeping people well and becoming the leading health system for preventative care. We're excited to help MetroHealth accomplish that goal."

About ChemistryWith offices in Atlanta and Pittsburgh, Chemistry combines the best elements of traditional and digital marketing to create positive reactions. As a full-service agency with more than 100 employees, it is constantly experimenting with new technologies and new media in the worlds of advertising, online marketing, media planning/buying, web design/development, mobile marketing and public relations. Chemistry provides solutions to a broad range of clients including the most respected brands in hospitality, healthcare and financial services. To learn more, visit createareaction.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/metrohealth-names-chemistry-agency-of-record-300466952.html

SOURCE Chemistry

Homepage

Excerpt from:
MetroHealth Names Chemistry Agency of Record - PR Newswire - PR Newswire (press release)

Value of EU to UK chemistry revealed – Chemistry World (subscription)

Chemistry is one of the big winners when it comes to EU research funding securing almost 55 million in 201415 alone. This is according to an analysis for the national academies, which found that chemistry was one of the top five disciplines when it came to attracting European research grants behind only clinical medicine, biosciences and physics. It also relies heavily on that funding: on average, EU grants accounted for 23% of departmental research income in the same year. This funding is now under threat with Britains planned exit from the EU.

Jason Love, head of inorganic chemistry at Edinburgh University isnt surprised: Its a broad subject so its able to get funding from medical research, biological research, more fundamental physical sciences research and materials. The breadth [] means we will collaborate widely. Moreover, there are a lot of challenges in chemistry that cant be solved in isolation. On average, over the past six years, 16% of his departments research funding has come from EU programmes.

Overall, higher education has taken the lions share of Horizon 2020 funding coming into the UK: over 1.93 billion (1.69 billion) by the end of 2016, equating to 63% of the total. Higher education institutions (HEI) arent so successful in other countries. To put the scale of EU investment in context, in 201415 HEIs reported 725 million in EU funding, which was 12% of their total income from grants and contracts, or around 25% of the 2.75 billion in research grants provided through UK government bodies.

The sector also attracts significant support from the European Regional Development Fund, and loans from the European Investment Bank which, according to the reports authors, Technopolis, have enabled research institutes to move forward earlier with more ambitious development plans. These endorsements from the bank can also be key in attracting other investors.

Amer Gaffar, director of the Manchester Fuel Cell Innovation Centre, says a 1.6 million award allowed Manchester Metropolitan University to get the centre off the ground quickly. Its doors will open at the end of the year and provide SMEs with equipment to develop hydrogen fuel cells. EU funding has also allowed his team to build partnerships across Europe that will be vital to the success of the centre.

EU research programmes provide unique personal grants and fellowships. During the Seventh Framework Programme (FP7) the predecessor to Horizon 2020 the UK won over 22% of European Research Council (ERC) grants. These not only provide science funding but enable us to attract international staff, which is incredibly important, says Claire Carmalt, head of chemistry at University College London. 1520% of her departments funding portfolio comes from the EU.

Last year one of its researchers won an ERC consolidator grant, which backs ground-breaking, risky research. The department, she adds, will leverage off the exciting science it supports. Edinburghs chemistry department also has two starting grants that help cement early stage careers. Love questions whether the UK government will offer more funds for early career researchers. These can really kick start a career or push on to important innovations, he notes.

Those grants also provide a flexibility not offered by UK funding sources. A lot of UK research council grants have an industrial or manufacturing focus [] whereas EU funding can have projects for fundamental science, says Carmalt. We need the fundamental research to get us to the applied.

Schemes such as the Marie Skodowska-Curie Actions, which support mobility between countries, are fantastic for bringing across really top people to the UK and help diversify talent, Carmalt adds. The UK has been very successful in winning these awards. But both Carmalt and Love are concerned that Brexit will mean losing academic staff from across the EU: How will we plug the gap? asks Carmalt. Edinburgh has already lost EU colleagues.

UK industry also gets substantial funding for research from the EU. In the first two years of Horizon 2020, companies received an average of 189 million a year. SMEs have been particularly successful, attracting more funding from Horizon 2020 and FP7, than any other country. It also accounts for a much higher proportion of R&D spend by SMEs than for the UK business sector as a whole. SMEs did particularly well in thematic funding such as ICT, nanosciences and materials.

Companies that took part in projects in FP7 report improved access to markets. Large companies also report significant benefits. The reports authors notes that the framework programmes facilitates strategic collaboration across Europe and helps underpin the innovation ecosystem by supporting the pipeline of ideas and talent from universities. They also point to the unique scale and reach of Horizon 2020 joint technology initiatives such as those on innovative medicines and hydrogen fuel cells, dwarf anything being done on a national scale.

Analysis suggests that public R&D expenditure like Horizon 2020 has a significant crowding-in effect, encouraging further private investment in R&D outside the programme. Studies suggest that for every 1 spent on R&D by the European commission, a further 0.74 will be invested by companies or other organisations in the wider EU economy. Technopolis argues that the effect could be stronger in an advanced economy like the UKs.

Read the rest here:
Value of EU to UK chemistry revealed - Chemistry World (subscription)

Tom Savage building chemistry with teammates | Texans Wire – Texans Wire

The last time Tom Savage entered a season as the presumptive starting quarterback was four years ago, when, as a senior, he guided the Pitt Panthers to a 6-6 record that culminated in a 30-27 victory in the Little CaesarsPizza Bowl.

Nearly five months after that game, which Savage was knocked out of early, the Houston Texans selected Savage in the fourth round of the 2014 NFL Draft. After waiting in the wings three seasons, the now 27-year-old signal caller will finally get his chance to become an NFL starter.

After three long years watching and learning head coach Bill OBriens complex offensive scheme, Savage entered OTAs as Houstons starting quarterback. Despite the acquisition of Deshaun Watson via the 2017NFL Draft, Savage plans on finishing 2017 as the starter.

To do that, Savage will need to build chemistry and rapport with his teammates on both sides of the ball. Accordingto Savage, getting the chance to practice against the leagues top defense is invaluable.

Its a good bonding experience obviously within the team, but the challenges are they are the Houston Texans defense, said Savage. Im realizing you have to get this ball out quick, especially with that front and those guys covering.

As difficult as its been, Savage seems to be enjoying the challenge.I love this because were all out there competing and were all kind of if you heard it were all yapping at each other. Its a good bonding experience.

Even more important for Savage and the rest of the Texans offense in OTAs is to work on timing, chemistry and getting the offense functioning as a unit much better than they did in 2016.

By opening OTAs as the starter, Savage is now receiving important first-team reps, which give him that opportunity to build a rapport with his lineman, backs and receivers.

Its helping a lot, Savage said about playing with the starters. We get a limited time, and we all have to meet extra a little bit after if we want to get better. Thats what it comes down to.

But Savage knows that while staying after practice with his pass catchers is important, lining up with the entire offense, going over cadences and learning to work as a cohesive unit is the most important take away from Mays OTAs.

Just repetition and stuff were doing after practice and extra meetings. We get a limited time, and we all have to meet extra a little bit after if we want to get better, said Savage. Thats what it comes down to.

Despite this being his first season as a starter, Savage isnt preparing differently than he has in his previous three seasons, but he understands he is now being counted on as a leader.

I think a little more of it is in the communication, obviously, with some of the guys. When youre a third-string quarterback, youre not really going up to DeAndre Hopkins and telling him how you want a bow route or something. Now communication comes in and you have to be on the same page with all of them. Thats what were working on now.

Entering his fourth season as a pro, Savage knows the spotlight will be on him. Its a great opportunity. I hate to say its special because I have to go out there and I have to earn it every day, said Savage.

Savage also knows in the NFL you must constantly earn playing time, so hes not necessarily ready to celebrate his new role. Perhaps with veteran savvy, Savage thinks there will be time to celebrate later.

Itll be special at the end of the season.

Read more:
Tom Savage building chemistry with teammates | Texans Wire - Texans Wire

Aaron Rodgers: OTAs are for building on-field chemistry – Packers Wire

Building chemistry with his new teammates remains the primary goal for Green Bay Packers quarterback Aaron Rodgers during organized team activities, which continue into the second phase this week.

I think at this point, when youre adding new guys to the mix, its about chemistry, Rodgers said last week. Thats the on the field chemistry. Its reading body language when theyre running routes, its getting on the same page with the verbiage when you have new players. And starting to figure out how guys like to run routes, where they like the ball in certain situations, how they use their body. Its about timing, and getting that chemistry with the new skill players.

The Packers have added a number of new pieces to the offense this offseason, including veteran tight ends Martellus Bennett and Lance Kendricks. Green Bay also drafted two young receivers (DeAngelo Yancey, Malachi Dupre) and rebuilt the running back position.

Building a rapport and understanding each new individuals wants and needs is necessary for keeping a high-octane offense running smoothly. The connection between Rodgers and Bennett the versatile tight end and teams replacement for playoff hero Jared Cook is especially important for ensuring the Packers hit the ground running to start 2017.

The two have already been working overtime to establish the on-field relationship.

Im always talking to him on the field, too, trying to see what he wants, Bennett said, according to Jason Wilde of the Wisconsin State Journal. (Ill say), Hey, how did that look? or hell give me the thumbs up. Or if Im in another group, I always look back at him, Hey, is that what you want? Is there something different you want on this? Always trying to figure out, just trying to have those conversations on and off the field, trying to get know each other as players, and as people.

Kendricks,who spent his first six years with the Rams, is also using OTAs to find his footing in a new environment.

New organization, new offense, new verbiage, new schemes and stuff, Kendricks said. Its going to take a little bit of time, I just gotta take it day-by-day. But Ill catch on.

The new tight ends still have ample opportunity to get on the same page with Rodgers and comfortable within the offense, especially considering the Packers emphasis on the passing game during OTAs.

Chemistry is really important, Rodgers said. Its about learning those guys, and their body movements, and what routes they feel good about and what routes they struggle with. Well have plenty of time, in these OTAs, a lot of individual time. Were not doing a lot of run plays, by design. It gives us a lot of time to work on the passing gameIm confident well be ready to go once the season starts.

Read the original:
Aaron Rodgers: OTAs are for building on-field chemistry - Packers Wire